Global Benign Prostatic Hyperplasia (BPH) Medication Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.
LPI (LP Information)' newest research report, the “Benign Prostatic Hyperplasia (BPH) Medication Industry Forecast” looks at past sales and reviews total world Benign Prostatic Hyperplasia (BPH) Medication sales in 2022, providing a comprehensive analysis by region and market sector of projected Benign Prostatic Hyperplasia (BPH) Medication sales for 2023 through 2029. With Benign Prostatic Hyperplasia (BPH) Medication sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Benign Prostatic Hyperplasia (BPH) Medication industry.
This Insight Report provides a comprehensive analysis of the global Benign Prostatic Hyperplasia (BPH) Medication landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Benign Prostatic Hyperplasia (BPH) Medication portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Benign Prostatic Hyperplasia (BPH) Medication market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Benign Prostatic Hyperplasia (BPH) Medication and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Benign Prostatic Hyperplasia (BPH) Medication.
The global Benign Prostatic Hyperplasia (BPH) Medication market size is projected to grow from US$ 3257.1 million in 2022 to US$ 4151.5 million in 2029; it is expected to grow at a CAGR of 4151.5 from 2023 to 2029.
North America is the largest consumption place, with a consumption market share nearly 38% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 27.6%. Market competition is intense. Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
This report presents a comprehensive overview, market shares, and growth opportunities of Benign Prostatic Hyperplasia (BPH) Medication market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Benign Prostatic Hyperplasia (BPH) Medication market?
What factors are driving Benign Prostatic Hyperplasia (BPH) Medication market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Benign Prostatic Hyperplasia (BPH) Medication market opportunities vary by end market size?
How does Benign Prostatic Hyperplasia (BPH) Medication break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.
LPI (LP Information)' newest research report, the “Benign Prostatic Hyperplasia (BPH) Medication Industry Forecast” looks at past sales and reviews total world Benign Prostatic Hyperplasia (BPH) Medication sales in 2022, providing a comprehensive analysis by region and market sector of projected Benign Prostatic Hyperplasia (BPH) Medication sales for 2023 through 2029. With Benign Prostatic Hyperplasia (BPH) Medication sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Benign Prostatic Hyperplasia (BPH) Medication industry.
This Insight Report provides a comprehensive analysis of the global Benign Prostatic Hyperplasia (BPH) Medication landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Benign Prostatic Hyperplasia (BPH) Medication portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Benign Prostatic Hyperplasia (BPH) Medication market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Benign Prostatic Hyperplasia (BPH) Medication and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Benign Prostatic Hyperplasia (BPH) Medication.
The global Benign Prostatic Hyperplasia (BPH) Medication market size is projected to grow from US$ 3257.1 million in 2022 to US$ 4151.5 million in 2029; it is expected to grow at a CAGR of 4151.5 from 2023 to 2029.
North America is the largest consumption place, with a consumption market share nearly 38% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 27.6%. Market competition is intense. Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
This report presents a comprehensive overview, market shares, and growth opportunities of Benign Prostatic Hyperplasia (BPH) Medication market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- 5-Alpha-Reductase Inhibitors
- Beta-Blockers
- Botanicals and Traditional Chinese Medicine
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Astellas Pharma
- Eli Lilly
- GlaxoSmithKline
- Sanofi
- ADC Therapeutics
- Bayer HealthCare
- Bristol-Myers Squibb
- Valeant Pharmaceuticals
- Endo Pharmaceuticals
- Foresee Pharmaceuticals
- Merck
- Novartis
- Advaxis
- Teva Pharmaceutical Industries
- Urologixs
- Agennix
- ANI Pharmaceuticals
- BHR Pharma
- Boehringer Ingelheim
- Sanpower Group
- Eisai
- Ferring
- IO THERAPEUTICS
- LIDDS
- Madrigal Pharmaceuticals
- Nymox Pharmaceutical
- Spectrum Pharmaceuticals
- Takeda Pharmaceuticals
What is the 10-year outlook for the global Benign Prostatic Hyperplasia (BPH) Medication market?
What factors are driving Benign Prostatic Hyperplasia (BPH) Medication market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Benign Prostatic Hyperplasia (BPH) Medication market opportunities vary by end market size?
How does Benign Prostatic Hyperplasia (BPH) Medication break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Benign Prostatic Hyperplasia (BPH) Medication Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Medication by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Medication by Country/Region, 2018, 2022 & 2029
2.2 Benign Prostatic Hyperplasia (BPH) Medication Segment by Type
2.2.1 5-Alpha-Reductase Inhibitors
2.2.2 Beta-Blockers
2.2.3 Botanicals and Traditional Chinese Medicine
2.3 Benign Prostatic Hyperplasia (BPH) Medication Sales by Type
2.3.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2018-2023)
2.3.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Type (2018-2023)
2.3.3 Global Benign Prostatic Hyperplasia (BPH) Medication Sale Price by Type (2018-2023)
2.4 Benign Prostatic Hyperplasia (BPH) Medication Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.5 Benign Prostatic Hyperplasia (BPH) Medication Sales by Application
2.5.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sale Market Share by Application (2018-2023)
2.5.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Application (2018-2023)
2.5.3 Global Benign Prostatic Hyperplasia (BPH) Medication Sale Price by Application (2018-2023)
3 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) MEDICATION BY COMPANY
3.1 Global Benign Prostatic Hyperplasia (BPH) Medication Breakdown Data by Company
3.1.1 Global Benign Prostatic Hyperplasia (BPH) Medication Annual Sales by Company (2018-2023)
3.1.2 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company (2018-2023)
3.2 Global Benign Prostatic Hyperplasia (BPH) Medication Annual Revenue by Company (2018-2023)
3.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Company (2018-2023)
3.2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Company (2018-2023)
3.3 Global Benign Prostatic Hyperplasia (BPH) Medication Sale Price by Company
3.4 Key Manufacturers Benign Prostatic Hyperplasia (BPH) Medication Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Benign Prostatic Hyperplasia (BPH) Medication Product Location Distribution
3.4.2 Players Benign Prostatic Hyperplasia (BPH) Medication Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR BENIGN PROSTATIC HYPERPLASIA (BPH) MEDICATION BY GEOGRAPHIC REGION
4.1 World Historic Benign Prostatic Hyperplasia (BPH) Medication Market Size by Geographic Region (2018-2023)
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Medication Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Medication Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Benign Prostatic Hyperplasia (BPH) Medication Market Size by Country/Region (2018-2023)
4.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Annual Sales by Country/Region (2018-2023)
4.2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Annual Revenue by Country/Region (2018-2023)
4.3 Americas Benign Prostatic Hyperplasia (BPH) Medication Sales Growth
4.4 APAC Benign Prostatic Hyperplasia (BPH) Medication Sales Growth
4.5 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Growth
4.6 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales Growth
5 AMERICAS
5.1 Americas Benign Prostatic Hyperplasia (BPH) Medication Sales by Country
5.1.1 Americas Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2018-2023)
5.1.2 Americas Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2018-2023)
5.2 Americas Benign Prostatic Hyperplasia (BPH) Medication Sales by Type
5.3 Americas Benign Prostatic Hyperplasia (BPH) Medication Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Benign Prostatic Hyperplasia (BPH) Medication Sales by Region
6.1.1 APAC Benign Prostatic Hyperplasia (BPH) Medication Sales by Region (2018-2023)
6.1.2 APAC Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region (2018-2023)
6.2 APAC Benign Prostatic Hyperplasia (BPH) Medication Sales by Type
6.3 APAC Benign Prostatic Hyperplasia (BPH) Medication Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Benign Prostatic Hyperplasia (BPH) Medication by Country
7.1.1 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2018-2023)
7.1.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2018-2023)
7.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Type
7.3 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication by Country
8.1.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2018-2023)
8.1.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2018-2023)
8.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Type
8.3 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Benign Prostatic Hyperplasia (BPH) Medication
10.3 Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Medication
10.4 Industry Chain Structure of Benign Prostatic Hyperplasia (BPH) Medication
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Benign Prostatic Hyperplasia (BPH) Medication Distributors
11.3 Benign Prostatic Hyperplasia (BPH) Medication Customer
12 WORLD FORECAST REVIEW FOR BENIGN PROSTATIC HYPERPLASIA (BPH) MEDICATION BY GEOGRAPHIC REGION
12.1 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size Forecast by Region
12.1.1 Global Benign Prostatic Hyperplasia (BPH) Medication Forecast by Region (2024-2029)
12.1.2 Global Benign Prostatic Hyperplasia (BPH) Medication Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Benign Prostatic Hyperplasia (BPH) Medication Forecast by Type
12.7 Global Benign Prostatic Hyperplasia (BPH) Medication Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Astellas Pharma
13.1.1 Astellas Pharma Company Information
13.1.2 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Astellas Pharma Main Business Overview
13.1.5 Astellas Pharma Latest Developments
13.2 Eli Lilly
13.2.1 Eli Lilly Company Information
13.2.2 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Eli Lilly Main Business Overview
13.2.5 Eli Lilly Latest Developments
13.3 GlaxoSmithKline
13.3.1 GlaxoSmithKline Company Information
13.3.2 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 GlaxoSmithKline Main Business Overview
13.3.5 GlaxoSmithKline Latest Developments
13.4 Sanofi
13.4.1 Sanofi Company Information
13.4.2 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Sanofi Main Business Overview
13.4.5 Sanofi Latest Developments
13.5 ADC Therapeutics
13.5.1 ADC Therapeutics Company Information
13.5.2 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.5.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 ADC Therapeutics Main Business Overview
13.5.5 ADC Therapeutics Latest Developments
13.6 Bayer HealthCare
13.6.1 Bayer HealthCare Company Information
13.6.2 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.6.3 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Bayer HealthCare Main Business Overview
13.6.5 Bayer HealthCare Latest Developments
13.7 Bristol-Myers Squibb
13.7.1 Bristol-Myers Squibb Company Information
13.7.2 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.7.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Bristol-Myers Squibb Main Business Overview
13.7.5 Bristol-Myers Squibb Latest Developments
13.8 Valeant Pharmaceuticals
13.8.1 Valeant Pharmaceuticals Company Information
13.8.2 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.8.3 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Valeant Pharmaceuticals Main Business Overview
13.8.5 Valeant Pharmaceuticals Latest Developments
13.9 Endo Pharmaceuticals
13.9.1 Endo Pharmaceuticals Company Information
13.9.2 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.9.3 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Endo Pharmaceuticals Main Business Overview
13.9.5 Endo Pharmaceuticals Latest Developments
13.10 Foresee Pharmaceuticals
13.10.1 Foresee Pharmaceuticals Company Information
13.10.2 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.10.3 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Foresee Pharmaceuticals Main Business Overview
13.10.5 Foresee Pharmaceuticals Latest Developments
13.11 Merck
13.11.1 Merck Company Information
13.11.2 Merck Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.11.3 Merck Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Merck Main Business Overview
13.11.5 Merck Latest Developments
13.12 Novartis
13.12.1 Novartis Company Information
13.12.2 Novartis Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.12.3 Novartis Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Novartis Main Business Overview
13.12.5 Novartis Latest Developments
13.13 Advaxis
13.13.1 Advaxis Company Information
13.13.2 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.13.3 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Advaxis Main Business Overview
13.13.5 Advaxis Latest Developments
13.14 Teva Pharmaceutical Industries
13.14.1 Teva Pharmaceutical Industries Company Information
13.14.2 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.14.3 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Teva Pharmaceutical Industries Main Business Overview
13.14.5 Teva Pharmaceutical Industries Latest Developments
13.15 Urologixs
13.15.1 Urologixs Company Information
13.15.2 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.15.3 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Urologixs Main Business Overview
13.15.5 Urologixs Latest Developments
13.16 Agennix
13.16.1 Agennix Company Information
13.16.2 Agennix Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.16.3 Agennix Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Agennix Main Business Overview
13.16.5 Agennix Latest Developments
13.17 ANI Pharmaceuticals
13.17.1 ANI Pharmaceuticals Company Information
13.17.2 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.17.3 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 ANI Pharmaceuticals Main Business Overview
13.17.5 ANI Pharmaceuticals Latest Developments
13.18 BHR Pharma
13.18.1 BHR Pharma Company Information
13.18.2 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.18.3 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 BHR Pharma Main Business Overview
13.18.5 BHR Pharma Latest Developments
13.19 Boehringer Ingelheim
13.19.1 Boehringer Ingelheim Company Information
13.19.2 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.19.3 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 Boehringer Ingelheim Main Business Overview
13.19.5 Boehringer Ingelheim Latest Developments
13.20 Sanpower Group
13.20.1 Sanpower Group Company Information
13.20.2 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.20.3 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.20.4 Sanpower Group Main Business Overview
13.20.5 Sanpower Group Latest Developments
13.21 Eisai
13.21.1 Eisai Company Information
13.21.2 Eisai Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.21.3 Eisai Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.21.4 Eisai Main Business Overview
13.21.5 Eisai Latest Developments
13.22 Ferring
13.22.1 Ferring Company Information
13.22.2 Ferring Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.22.3 Ferring Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.22.4 Ferring Main Business Overview
13.22.5 Ferring Latest Developments
13.23 IO THERAPEUTICS
13.23.1 IO THERAPEUTICS Company Information
13.23.2 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.23.3 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.23.4 IO THERAPEUTICS Main Business Overview
13.23.5 IO THERAPEUTICS Latest Developments
13.24 LIDDS
13.24.1 LIDDS Company Information
13.24.2 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.24.3 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.24.4 LIDDS Main Business Overview
13.24.5 LIDDS Latest Developments
13.25 Madrigal Pharmaceuticals
13.25.1 Madrigal Pharmaceuticals Company Information
13.25.2 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.25.3 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.25.4 Madrigal Pharmaceuticals Main Business Overview
13.25.5 Madrigal Pharmaceuticals Latest Developments
13.26 Nymox Pharmaceutical
13.26.1 Nymox Pharmaceutical Company Information
13.26.2 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.26.3 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.26.4 Nymox Pharmaceutical Main Business Overview
13.26.5 Nymox Pharmaceutical Latest Developments
13.27 Spectrum Pharmaceuticals
13.27.1 Spectrum Pharmaceuticals Company Information
13.27.2 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.27.3 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.27.4 Spectrum Pharmaceuticals Main Business Overview
13.27.5 Spectrum Pharmaceuticals Latest Developments
13.28 Takeda Pharmaceuticals
13.28.1 Takeda Pharmaceuticals Company Information
13.28.2 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.28.3 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.28.4 Takeda Pharmaceuticals Main Business Overview
13.28.5 Takeda Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Benign Prostatic Hyperplasia (BPH) Medication Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Medication by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Medication by Country/Region, 2018, 2022 & 2029
2.2 Benign Prostatic Hyperplasia (BPH) Medication Segment by Type
2.2.1 5-Alpha-Reductase Inhibitors
2.2.2 Beta-Blockers
2.2.3 Botanicals and Traditional Chinese Medicine
2.3 Benign Prostatic Hyperplasia (BPH) Medication Sales by Type
2.3.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2018-2023)
2.3.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Type (2018-2023)
2.3.3 Global Benign Prostatic Hyperplasia (BPH) Medication Sale Price by Type (2018-2023)
2.4 Benign Prostatic Hyperplasia (BPH) Medication Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.5 Benign Prostatic Hyperplasia (BPH) Medication Sales by Application
2.5.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sale Market Share by Application (2018-2023)
2.5.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Application (2018-2023)
2.5.3 Global Benign Prostatic Hyperplasia (BPH) Medication Sale Price by Application (2018-2023)
3 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) MEDICATION BY COMPANY
3.1 Global Benign Prostatic Hyperplasia (BPH) Medication Breakdown Data by Company
3.1.1 Global Benign Prostatic Hyperplasia (BPH) Medication Annual Sales by Company (2018-2023)
3.1.2 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company (2018-2023)
3.2 Global Benign Prostatic Hyperplasia (BPH) Medication Annual Revenue by Company (2018-2023)
3.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Company (2018-2023)
3.2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Company (2018-2023)
3.3 Global Benign Prostatic Hyperplasia (BPH) Medication Sale Price by Company
3.4 Key Manufacturers Benign Prostatic Hyperplasia (BPH) Medication Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Benign Prostatic Hyperplasia (BPH) Medication Product Location Distribution
3.4.2 Players Benign Prostatic Hyperplasia (BPH) Medication Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR BENIGN PROSTATIC HYPERPLASIA (BPH) MEDICATION BY GEOGRAPHIC REGION
4.1 World Historic Benign Prostatic Hyperplasia (BPH) Medication Market Size by Geographic Region (2018-2023)
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Medication Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Medication Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Benign Prostatic Hyperplasia (BPH) Medication Market Size by Country/Region (2018-2023)
4.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Annual Sales by Country/Region (2018-2023)
4.2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Annual Revenue by Country/Region (2018-2023)
4.3 Americas Benign Prostatic Hyperplasia (BPH) Medication Sales Growth
4.4 APAC Benign Prostatic Hyperplasia (BPH) Medication Sales Growth
4.5 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Growth
4.6 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales Growth
5 AMERICAS
5.1 Americas Benign Prostatic Hyperplasia (BPH) Medication Sales by Country
5.1.1 Americas Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2018-2023)
5.1.2 Americas Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2018-2023)
5.2 Americas Benign Prostatic Hyperplasia (BPH) Medication Sales by Type
5.3 Americas Benign Prostatic Hyperplasia (BPH) Medication Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Benign Prostatic Hyperplasia (BPH) Medication Sales by Region
6.1.1 APAC Benign Prostatic Hyperplasia (BPH) Medication Sales by Region (2018-2023)
6.1.2 APAC Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region (2018-2023)
6.2 APAC Benign Prostatic Hyperplasia (BPH) Medication Sales by Type
6.3 APAC Benign Prostatic Hyperplasia (BPH) Medication Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Benign Prostatic Hyperplasia (BPH) Medication by Country
7.1.1 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2018-2023)
7.1.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2018-2023)
7.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Type
7.3 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication by Country
8.1.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2018-2023)
8.1.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2018-2023)
8.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Type
8.3 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Benign Prostatic Hyperplasia (BPH) Medication
10.3 Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Medication
10.4 Industry Chain Structure of Benign Prostatic Hyperplasia (BPH) Medication
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Benign Prostatic Hyperplasia (BPH) Medication Distributors
11.3 Benign Prostatic Hyperplasia (BPH) Medication Customer
12 WORLD FORECAST REVIEW FOR BENIGN PROSTATIC HYPERPLASIA (BPH) MEDICATION BY GEOGRAPHIC REGION
12.1 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size Forecast by Region
12.1.1 Global Benign Prostatic Hyperplasia (BPH) Medication Forecast by Region (2024-2029)
12.1.2 Global Benign Prostatic Hyperplasia (BPH) Medication Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Benign Prostatic Hyperplasia (BPH) Medication Forecast by Type
12.7 Global Benign Prostatic Hyperplasia (BPH) Medication Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Astellas Pharma
13.1.1 Astellas Pharma Company Information
13.1.2 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Astellas Pharma Main Business Overview
13.1.5 Astellas Pharma Latest Developments
13.2 Eli Lilly
13.2.1 Eli Lilly Company Information
13.2.2 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Eli Lilly Main Business Overview
13.2.5 Eli Lilly Latest Developments
13.3 GlaxoSmithKline
13.3.1 GlaxoSmithKline Company Information
13.3.2 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 GlaxoSmithKline Main Business Overview
13.3.5 GlaxoSmithKline Latest Developments
13.4 Sanofi
13.4.1 Sanofi Company Information
13.4.2 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Sanofi Main Business Overview
13.4.5 Sanofi Latest Developments
13.5 ADC Therapeutics
13.5.1 ADC Therapeutics Company Information
13.5.2 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.5.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 ADC Therapeutics Main Business Overview
13.5.5 ADC Therapeutics Latest Developments
13.6 Bayer HealthCare
13.6.1 Bayer HealthCare Company Information
13.6.2 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.6.3 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Bayer HealthCare Main Business Overview
13.6.5 Bayer HealthCare Latest Developments
13.7 Bristol-Myers Squibb
13.7.1 Bristol-Myers Squibb Company Information
13.7.2 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.7.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Bristol-Myers Squibb Main Business Overview
13.7.5 Bristol-Myers Squibb Latest Developments
13.8 Valeant Pharmaceuticals
13.8.1 Valeant Pharmaceuticals Company Information
13.8.2 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.8.3 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Valeant Pharmaceuticals Main Business Overview
13.8.5 Valeant Pharmaceuticals Latest Developments
13.9 Endo Pharmaceuticals
13.9.1 Endo Pharmaceuticals Company Information
13.9.2 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.9.3 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Endo Pharmaceuticals Main Business Overview
13.9.5 Endo Pharmaceuticals Latest Developments
13.10 Foresee Pharmaceuticals
13.10.1 Foresee Pharmaceuticals Company Information
13.10.2 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.10.3 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Foresee Pharmaceuticals Main Business Overview
13.10.5 Foresee Pharmaceuticals Latest Developments
13.11 Merck
13.11.1 Merck Company Information
13.11.2 Merck Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.11.3 Merck Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Merck Main Business Overview
13.11.5 Merck Latest Developments
13.12 Novartis
13.12.1 Novartis Company Information
13.12.2 Novartis Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.12.3 Novartis Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Novartis Main Business Overview
13.12.5 Novartis Latest Developments
13.13 Advaxis
13.13.1 Advaxis Company Information
13.13.2 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.13.3 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Advaxis Main Business Overview
13.13.5 Advaxis Latest Developments
13.14 Teva Pharmaceutical Industries
13.14.1 Teva Pharmaceutical Industries Company Information
13.14.2 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.14.3 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Teva Pharmaceutical Industries Main Business Overview
13.14.5 Teva Pharmaceutical Industries Latest Developments
13.15 Urologixs
13.15.1 Urologixs Company Information
13.15.2 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.15.3 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Urologixs Main Business Overview
13.15.5 Urologixs Latest Developments
13.16 Agennix
13.16.1 Agennix Company Information
13.16.2 Agennix Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.16.3 Agennix Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Agennix Main Business Overview
13.16.5 Agennix Latest Developments
13.17 ANI Pharmaceuticals
13.17.1 ANI Pharmaceuticals Company Information
13.17.2 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.17.3 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 ANI Pharmaceuticals Main Business Overview
13.17.5 ANI Pharmaceuticals Latest Developments
13.18 BHR Pharma
13.18.1 BHR Pharma Company Information
13.18.2 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.18.3 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 BHR Pharma Main Business Overview
13.18.5 BHR Pharma Latest Developments
13.19 Boehringer Ingelheim
13.19.1 Boehringer Ingelheim Company Information
13.19.2 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.19.3 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 Boehringer Ingelheim Main Business Overview
13.19.5 Boehringer Ingelheim Latest Developments
13.20 Sanpower Group
13.20.1 Sanpower Group Company Information
13.20.2 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.20.3 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.20.4 Sanpower Group Main Business Overview
13.20.5 Sanpower Group Latest Developments
13.21 Eisai
13.21.1 Eisai Company Information
13.21.2 Eisai Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.21.3 Eisai Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.21.4 Eisai Main Business Overview
13.21.5 Eisai Latest Developments
13.22 Ferring
13.22.1 Ferring Company Information
13.22.2 Ferring Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.22.3 Ferring Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.22.4 Ferring Main Business Overview
13.22.5 Ferring Latest Developments
13.23 IO THERAPEUTICS
13.23.1 IO THERAPEUTICS Company Information
13.23.2 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.23.3 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.23.4 IO THERAPEUTICS Main Business Overview
13.23.5 IO THERAPEUTICS Latest Developments
13.24 LIDDS
13.24.1 LIDDS Company Information
13.24.2 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.24.3 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.24.4 LIDDS Main Business Overview
13.24.5 LIDDS Latest Developments
13.25 Madrigal Pharmaceuticals
13.25.1 Madrigal Pharmaceuticals Company Information
13.25.2 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.25.3 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.25.4 Madrigal Pharmaceuticals Main Business Overview
13.25.5 Madrigal Pharmaceuticals Latest Developments
13.26 Nymox Pharmaceutical
13.26.1 Nymox Pharmaceutical Company Information
13.26.2 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.26.3 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.26.4 Nymox Pharmaceutical Main Business Overview
13.26.5 Nymox Pharmaceutical Latest Developments
13.27 Spectrum Pharmaceuticals
13.27.1 Spectrum Pharmaceuticals Company Information
13.27.2 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.27.3 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.27.4 Spectrum Pharmaceuticals Main Business Overview
13.27.5 Spectrum Pharmaceuticals Latest Developments
13.28 Takeda Pharmaceuticals
13.28.1 Takeda Pharmaceuticals Company Information
13.28.2 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
13.28.3 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
13.28.4 Takeda Pharmaceuticals Main Business Overview
13.28.5 Takeda Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Benign Prostatic Hyperplasia (BPH) Medication Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Benign Prostatic Hyperplasia (BPH) Medication Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of 5-Alpha-Reductase Inhibitors
Table 4. Major Players of Beta-Blockers
Table 5. Major Players of Botanicals and Traditional Chinese Medicine
Table 6. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2018-2023) & (KG)
Table 7. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2018-2023)
Table 8. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Type (2018-2023) & ($ million)
Table 9. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Type (2018-2023)
Table 10. Global Benign Prostatic Hyperplasia (BPH) Medication Sale Price by Type (2018-2023) & (USD/KG)
Table 11. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2018-2023) & (KG)
Table 12. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2018-2023)
Table 13. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Application (2018-2023)
Table 14. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Application (2018-2023)
Table 15. Global Benign Prostatic Hyperplasia (BPH) Medication Sale Price by Application (2018-2023) & (USD/KG)
Table 16. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Company (2018-2023) & (KG)
Table 17. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company (2018-2023)
Table 18. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Company (2018-2023)
Table 20. Global Benign Prostatic Hyperplasia (BPH) Medication Sale Price by Company (2018-2023) & (USD/KG)
Table 21. Key Manufacturers Benign Prostatic Hyperplasia (BPH) Medication Producing Area Distribution and Sales Area
Table 22. Players Benign Prostatic Hyperplasia (BPH) Medication Products Offered
Table 23. Benign Prostatic Hyperplasia (BPH) Medication Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Geographic Region (2018-2023) & (KG)
Table 27. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share Geographic Region (2018-2023)
Table 28. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Country/Region (2018-2023) & (KG)
Table 31. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country/Region (2018-2023)
Table 32. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2018-2023) & (KG)
Table 35. Americas Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country (2018-2023)
Table 36. Americas Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country (2018-2023)
Table 38. Americas Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2018-2023) & (KG)
Table 39. Americas Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2018-2023) & (KG)
Table 40. APAC Benign Prostatic Hyperplasia (BPH) Medication Sales by Region (2018-2023) & (KG)
Table 41. APAC Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Region (2018-2023)
Table 42. APAC Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Region (2018-2023)
Table 44. APAC Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2018-2023) & (KG)
Table 45. APAC Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2018-2023) & (KG)
Table 46. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2018-2023) & (KG)
Table 47. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country (2018-2023)
Table 48. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country (2018-2023)
Table 50. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2018-2023) & (KG)
Table 51. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2018-2023) & (KG)
Table 52. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2018-2023) & (KG)
Table 53. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2018-2023) & (KG)
Table 57. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2018-2023) & (KG)
Table 58. Key Market Drivers & Growth Opportunities of Benign Prostatic Hyperplasia (BPH) Medication
Table 59. Key Market Challenges & Risks of Benign Prostatic Hyperplasia (BPH) Medication
Table 60. Key Industry Trends of Benign Prostatic Hyperplasia (BPH) Medication
Table 61. Benign Prostatic Hyperplasia (BPH) Medication Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Benign Prostatic Hyperplasia (BPH) Medication Distributors List
Table 64. Benign Prostatic Hyperplasia (BPH) Medication Customer List
Table 65. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Region (2024-2029) & (KG)
Table 66. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Country (2024-2029) & (KG)
Table 68. Americas Benign Prostatic Hyperplasia (BPH) Medication Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Region (2024-2029) & (KG)
Table 70. APAC Benign Prostatic Hyperplasia (BPH) Medication Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Country (2024-2029) & (KG)
Table 72. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Country (2024-2029) & (KG)
Table 74. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Type (2024-2029) & (KG)
Table 76. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Application (2024-2029) & (KG)
Table 78. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Astellas Pharma Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 80. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 81. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 82. Astellas Pharma Main Business
Table 83. Astellas Pharma Latest Developments
Table 84. Eli Lilly Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 85. Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 86. Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 87. Eli Lilly Main Business
Table 88. Eli Lilly Latest Developments
Table 89. GlaxoSmithKline Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 90. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 91. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 92. GlaxoSmithKline Main Business
Table 93. GlaxoSmithKline Latest Developments
Table 94. Sanofi Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 95. Sanofi Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 96. Sanofi Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 97. Sanofi Main Business
Table 98. Sanofi Latest Developments
Table 99. ADC Therapeutics Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 100. ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 101. ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 102. ADC Therapeutics Main Business
Table 103. ADC Therapeutics Latest Developments
Table 104. Bayer HealthCare Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 105. Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 106. Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 107. Bayer HealthCare Main Business
Table 108. Bayer HealthCare Latest Developments
Table 109. Bristol-Myers Squibb Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 110. Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 111. Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 112. Bristol-Myers Squibb Main Business
Table 113. Bristol-Myers Squibb Latest Developments
Table 114. Valeant Pharmaceuticals Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 115. Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 116. Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 117. Valeant Pharmaceuticals Main Business
Table 118. Valeant Pharmaceuticals Latest Developments
Table 119. Endo Pharmaceuticals Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 120. Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 121. Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 122. Endo Pharmaceuticals Main Business
Table 123. Endo Pharmaceuticals Latest Developments
Table 124. Foresee Pharmaceuticals Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 125. Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 126. Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 127. Foresee Pharmaceuticals Main Business
Table 128. Foresee Pharmaceuticals Latest Developments
Table 129. Merck Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 130. Merck Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 131. Merck Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 132. Merck Main Business
Table 133. Merck Latest Developments
Table 134. Novartis Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 135. Novartis Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 136. Novartis Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 137. Novartis Main Business
Table 138. Novartis Latest Developments
Table 139. Advaxis Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 140. Advaxis Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 141. Advaxis Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 142. Advaxis Main Business
Table 143. Advaxis Latest Developments
Table 144. Teva Pharmaceutical Industries Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 145. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 146. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 147. Teva Pharmaceutical Industries Main Business
Table 148. Teva Pharmaceutical Industries Latest Developments
Table 149. Urologixs Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 150. Urologixs Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 151. Urologixs Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 152. Urologixs Main Business
Table 153. Urologixs Latest Developments
Table 154. Agennix Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 155. Agennix Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 156. Agennix Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 157. Agennix Main Business
Table 158. Agennix Latest Developments
Table 159. ANI Pharmaceuticals Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 160. ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 161. ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 162. ANI Pharmaceuticals Main Business
Table 163. ANI Pharmaceuticals Latest Developments
Table 164. BHR Pharma Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 165. BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 166. BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 167. BHR Pharma Main Business
Table 168. BHR Pharma Latest Developments
Table 169. Boehringer Ingelheim Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 170. Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 171. Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 172. Boehringer Ingelheim Main Business
Table 173. Boehringer Ingelheim Latest Developments
Table 174. Sanpower Group Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 175. Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 176. Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 177. Sanpower Group Main Business
Table 178. Sanpower Group Latest Developments
Table 179. Eisai Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 180. Eisai Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 181. Eisai Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 182. Eisai Main Business
Table 183. Eisai Latest Developments
Table 184. Ferring Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 185. Ferring Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 186. Ferring Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 187. Ferring Main Business
Table 188. Ferring Latest Developments
Table 189. IO THERAPEUTICS Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 190. IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 191. IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 192. IO THERAPEUTICS Main Business
Table 193. IO THERAPEUTICS Latest Developments
Table 194. LIDDS Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 195. LIDDS Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 196. LIDDS Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 197. LIDDS Main Business
Table 198. LIDDS Latest Developments
Table 199. Madrigal Pharmaceuticals Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 200. Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 201. Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 202. Madrigal Pharmaceuticals Main Business
Table 203. Madrigal Pharmaceuticals Latest Developments
Table 204. Nymox Pharmaceutical Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 205. Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 206. Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 207. Nymox Pharmaceutical Main Business
Table 208. Nymox Pharmaceutical Latest Developments
Table 209. Spectrum Pharmaceuticals Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 210. Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 211. Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 212. Spectrum Pharmaceuticals Main Business
Table 213. Spectrum Pharmaceuticals Latest Developments
Table 214. Takeda Pharmaceuticals Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 215. Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 216. Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 217. Takeda Pharmaceuticals Main Business
Table 218. Takeda Pharmaceuticals Latest Developments
Table 1. Benign Prostatic Hyperplasia (BPH) Medication Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Benign Prostatic Hyperplasia (BPH) Medication Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of 5-Alpha-Reductase Inhibitors
Table 4. Major Players of Beta-Blockers
Table 5. Major Players of Botanicals and Traditional Chinese Medicine
Table 6. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2018-2023) & (KG)
Table 7. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2018-2023)
Table 8. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Type (2018-2023) & ($ million)
Table 9. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Type (2018-2023)
Table 10. Global Benign Prostatic Hyperplasia (BPH) Medication Sale Price by Type (2018-2023) & (USD/KG)
Table 11. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2018-2023) & (KG)
Table 12. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2018-2023)
Table 13. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Application (2018-2023)
Table 14. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Application (2018-2023)
Table 15. Global Benign Prostatic Hyperplasia (BPH) Medication Sale Price by Application (2018-2023) & (USD/KG)
Table 16. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Company (2018-2023) & (KG)
Table 17. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company (2018-2023)
Table 18. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Company (2018-2023)
Table 20. Global Benign Prostatic Hyperplasia (BPH) Medication Sale Price by Company (2018-2023) & (USD/KG)
Table 21. Key Manufacturers Benign Prostatic Hyperplasia (BPH) Medication Producing Area Distribution and Sales Area
Table 22. Players Benign Prostatic Hyperplasia (BPH) Medication Products Offered
Table 23. Benign Prostatic Hyperplasia (BPH) Medication Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Geographic Region (2018-2023) & (KG)
Table 27. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share Geographic Region (2018-2023)
Table 28. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Country/Region (2018-2023) & (KG)
Table 31. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country/Region (2018-2023)
Table 32. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2018-2023) & (KG)
Table 35. Americas Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country (2018-2023)
Table 36. Americas Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country (2018-2023)
Table 38. Americas Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2018-2023) & (KG)
Table 39. Americas Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2018-2023) & (KG)
Table 40. APAC Benign Prostatic Hyperplasia (BPH) Medication Sales by Region (2018-2023) & (KG)
Table 41. APAC Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Region (2018-2023)
Table 42. APAC Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Region (2018-2023)
Table 44. APAC Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2018-2023) & (KG)
Table 45. APAC Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2018-2023) & (KG)
Table 46. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2018-2023) & (KG)
Table 47. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country (2018-2023)
Table 48. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country (2018-2023)
Table 50. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2018-2023) & (KG)
Table 51. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2018-2023) & (KG)
Table 52. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2018-2023) & (KG)
Table 53. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2018-2023) & (KG)
Table 57. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2018-2023) & (KG)
Table 58. Key Market Drivers & Growth Opportunities of Benign Prostatic Hyperplasia (BPH) Medication
Table 59. Key Market Challenges & Risks of Benign Prostatic Hyperplasia (BPH) Medication
Table 60. Key Industry Trends of Benign Prostatic Hyperplasia (BPH) Medication
Table 61. Benign Prostatic Hyperplasia (BPH) Medication Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Benign Prostatic Hyperplasia (BPH) Medication Distributors List
Table 64. Benign Prostatic Hyperplasia (BPH) Medication Customer List
Table 65. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Region (2024-2029) & (KG)
Table 66. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Country (2024-2029) & (KG)
Table 68. Americas Benign Prostatic Hyperplasia (BPH) Medication Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Region (2024-2029) & (KG)
Table 70. APAC Benign Prostatic Hyperplasia (BPH) Medication Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Country (2024-2029) & (KG)
Table 72. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Country (2024-2029) & (KG)
Table 74. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Type (2024-2029) & (KG)
Table 76. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Application (2024-2029) & (KG)
Table 78. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Astellas Pharma Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 80. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 81. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 82. Astellas Pharma Main Business
Table 83. Astellas Pharma Latest Developments
Table 84. Eli Lilly Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 85. Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 86. Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 87. Eli Lilly Main Business
Table 88. Eli Lilly Latest Developments
Table 89. GlaxoSmithKline Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 90. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 91. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 92. GlaxoSmithKline Main Business
Table 93. GlaxoSmithKline Latest Developments
Table 94. Sanofi Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 95. Sanofi Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 96. Sanofi Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 97. Sanofi Main Business
Table 98. Sanofi Latest Developments
Table 99. ADC Therapeutics Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 100. ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 101. ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 102. ADC Therapeutics Main Business
Table 103. ADC Therapeutics Latest Developments
Table 104. Bayer HealthCare Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 105. Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 106. Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 107. Bayer HealthCare Main Business
Table 108. Bayer HealthCare Latest Developments
Table 109. Bristol-Myers Squibb Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 110. Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 111. Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 112. Bristol-Myers Squibb Main Business
Table 113. Bristol-Myers Squibb Latest Developments
Table 114. Valeant Pharmaceuticals Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 115. Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 116. Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 117. Valeant Pharmaceuticals Main Business
Table 118. Valeant Pharmaceuticals Latest Developments
Table 119. Endo Pharmaceuticals Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 120. Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 121. Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 122. Endo Pharmaceuticals Main Business
Table 123. Endo Pharmaceuticals Latest Developments
Table 124. Foresee Pharmaceuticals Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 125. Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 126. Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 127. Foresee Pharmaceuticals Main Business
Table 128. Foresee Pharmaceuticals Latest Developments
Table 129. Merck Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 130. Merck Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 131. Merck Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 132. Merck Main Business
Table 133. Merck Latest Developments
Table 134. Novartis Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 135. Novartis Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 136. Novartis Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 137. Novartis Main Business
Table 138. Novartis Latest Developments
Table 139. Advaxis Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 140. Advaxis Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 141. Advaxis Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 142. Advaxis Main Business
Table 143. Advaxis Latest Developments
Table 144. Teva Pharmaceutical Industries Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 145. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 146. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 147. Teva Pharmaceutical Industries Main Business
Table 148. Teva Pharmaceutical Industries Latest Developments
Table 149. Urologixs Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 150. Urologixs Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 151. Urologixs Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 152. Urologixs Main Business
Table 153. Urologixs Latest Developments
Table 154. Agennix Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 155. Agennix Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 156. Agennix Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 157. Agennix Main Business
Table 158. Agennix Latest Developments
Table 159. ANI Pharmaceuticals Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 160. ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 161. ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 162. ANI Pharmaceuticals Main Business
Table 163. ANI Pharmaceuticals Latest Developments
Table 164. BHR Pharma Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 165. BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 166. BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 167. BHR Pharma Main Business
Table 168. BHR Pharma Latest Developments
Table 169. Boehringer Ingelheim Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 170. Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 171. Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 172. Boehringer Ingelheim Main Business
Table 173. Boehringer Ingelheim Latest Developments
Table 174. Sanpower Group Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 175. Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 176. Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 177. Sanpower Group Main Business
Table 178. Sanpower Group Latest Developments
Table 179. Eisai Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 180. Eisai Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 181. Eisai Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 182. Eisai Main Business
Table 183. Eisai Latest Developments
Table 184. Ferring Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 185. Ferring Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 186. Ferring Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 187. Ferring Main Business
Table 188. Ferring Latest Developments
Table 189. IO THERAPEUTICS Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 190. IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 191. IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 192. IO THERAPEUTICS Main Business
Table 193. IO THERAPEUTICS Latest Developments
Table 194. LIDDS Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 195. LIDDS Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 196. LIDDS Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 197. LIDDS Main Business
Table 198. LIDDS Latest Developments
Table 199. Madrigal Pharmaceuticals Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 200. Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 201. Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 202. Madrigal Pharmaceuticals Main Business
Table 203. Madrigal Pharmaceuticals Latest Developments
Table 204. Nymox Pharmaceutical Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 205. Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 206. Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 207. Nymox Pharmaceutical Main Business
Table 208. Nymox Pharmaceutical Latest Developments
Table 209. Spectrum Pharmaceuticals Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 210. Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 211. Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 212. Spectrum Pharmaceuticals Main Business
Table 213. Spectrum Pharmaceuticals Latest Developments
Table 214. Takeda Pharmaceuticals Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 215. Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 216. Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue ($ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 217. Takeda Pharmaceuticals Main Business
Table 218. Takeda Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Picture of Benign Prostatic Hyperplasia (BPH) Medication
Figure 2. Benign Prostatic Hyperplasia (BPH) Medication Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Growth Rate 2018-2029 (KG)
Figure 7. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Benign Prostatic Hyperplasia (BPH) Medication Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of 5-Alpha-Reductase Inhibitors
Figure 10. Product Picture of Beta-Blockers
Figure 11. Product Picture of Botanicals and Traditional Chinese Medicine
Figure 12. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type in 2022
Figure 13. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Type (2018-2023)
Figure 14. Benign Prostatic Hyperplasia (BPH) Medication Consumed in Hospital Pharmacies
Figure 15. Global Benign Prostatic Hyperplasia (BPH) Medication Market: Hospital Pharmacies (2018-2023) & (KG)
Figure 16. Benign Prostatic Hyperplasia (BPH) Medication Consumed in Retail Pharmacies
Figure 17. Global Benign Prostatic Hyperplasia (BPH) Medication Market: Retail Pharmacies (2018-2023) & (KG)
Figure 18. Benign Prostatic Hyperplasia (BPH) Medication Consumed in Online Pharmacies
Figure 19. Global Benign Prostatic Hyperplasia (BPH) Medication Market: Online Pharmacies (2018-2023) & (KG)
Figure 20. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2022)
Figure 21. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Application in 2022
Figure 22. Benign Prostatic Hyperplasia (BPH) Medication Sales Market by Company in 2022 (KG)
Figure 23. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company in 2022
Figure 24. Benign Prostatic Hyperplasia (BPH) Medication Revenue Market by Company in 2022 ($ Million)
Figure 25. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Company in 2022
Figure 26. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Geographic Region (2018-2023)
Figure 27. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Geographic Region in 2022
Figure 28. Americas Benign Prostatic Hyperplasia (BPH) Medication Sales 2018-2023 (KG)
Figure 29. Americas Benign Prostatic Hyperplasia (BPH) Medication Revenue 2018-2023 ($ Millions)
Figure 30. APAC Benign Prostatic Hyperplasia (BPH) Medication Sales 2018-2023 (KG)
Figure 31. APAC Benign Prostatic Hyperplasia (BPH) Medication Revenue 2018-2023 ($ Millions)
Figure 32. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales 2018-2023 (KG)
Figure 33. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue 2018-2023 ($ Millions)
Figure 34. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales 2018-2023 (KG)
Figure 35. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue 2018-2023 ($ Millions)
Figure 36. Americas Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country in 2022
Figure 37. Americas Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country in 2022
Figure 38. Americas Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2018-2023)
Figure 39. Americas Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2018-2023)
Figure 40. United States Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 41. Canada Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 42. Mexico Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 43. Brazil Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 44. APAC Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Region in 2022
Figure 45. APAC Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Regions in 2022
Figure 46. APAC Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2018-2023)
Figure 47. APAC Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2018-2023)
Figure 48. China Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 49. Japan Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 50. South Korea Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 51. Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 52. India Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 53. Australia Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 54. China Taiwan Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 55. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country in 2022
Figure 56. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country in 2022
Figure 57. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2018-2023)
Figure 58. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2018-2023)
Figure 59. Germany Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 60. France Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 61. UK Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 62. Italy Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 63. Russia Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 64. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country in 2022
Figure 65. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country in 2022
Figure 66. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2018-2023)
Figure 67. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2018-2023)
Figure 68. Egypt Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 69. South Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 70. Israel Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 71. Turkey Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 72. GCC Country Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 73. Manufacturing Cost Structure Analysis of Benign Prostatic Hyperplasia (BPH) Medication in 2022
Figure 74. Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Medication
Figure 75. Industry Chain Structure of Benign Prostatic Hyperplasia (BPH) Medication
Figure 76. Channels of Distribution
Figure 77. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Forecast by Region (2024-2029)
Figure 78. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share Forecast by Region (2024-2029)
Figure 79. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share Forecast by Type (2024-2029)
Figure 80. Global Benign Prostatic Hyperplasia (BPH) Medication
Figure 1. Picture of Benign Prostatic Hyperplasia (BPH) Medication
Figure 2. Benign Prostatic Hyperplasia (BPH) Medication Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Growth Rate 2018-2029 (KG)
Figure 7. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Benign Prostatic Hyperplasia (BPH) Medication Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of 5-Alpha-Reductase Inhibitors
Figure 10. Product Picture of Beta-Blockers
Figure 11. Product Picture of Botanicals and Traditional Chinese Medicine
Figure 12. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type in 2022
Figure 13. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Type (2018-2023)
Figure 14. Benign Prostatic Hyperplasia (BPH) Medication Consumed in Hospital Pharmacies
Figure 15. Global Benign Prostatic Hyperplasia (BPH) Medication Market: Hospital Pharmacies (2018-2023) & (KG)
Figure 16. Benign Prostatic Hyperplasia (BPH) Medication Consumed in Retail Pharmacies
Figure 17. Global Benign Prostatic Hyperplasia (BPH) Medication Market: Retail Pharmacies (2018-2023) & (KG)
Figure 18. Benign Prostatic Hyperplasia (BPH) Medication Consumed in Online Pharmacies
Figure 19. Global Benign Prostatic Hyperplasia (BPH) Medication Market: Online Pharmacies (2018-2023) & (KG)
Figure 20. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2022)
Figure 21. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Application in 2022
Figure 22. Benign Prostatic Hyperplasia (BPH) Medication Sales Market by Company in 2022 (KG)
Figure 23. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company in 2022
Figure 24. Benign Prostatic Hyperplasia (BPH) Medication Revenue Market by Company in 2022 ($ Million)
Figure 25. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Company in 2022
Figure 26. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Geographic Region (2018-2023)
Figure 27. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Geographic Region in 2022
Figure 28. Americas Benign Prostatic Hyperplasia (BPH) Medication Sales 2018-2023 (KG)
Figure 29. Americas Benign Prostatic Hyperplasia (BPH) Medication Revenue 2018-2023 ($ Millions)
Figure 30. APAC Benign Prostatic Hyperplasia (BPH) Medication Sales 2018-2023 (KG)
Figure 31. APAC Benign Prostatic Hyperplasia (BPH) Medication Revenue 2018-2023 ($ Millions)
Figure 32. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales 2018-2023 (KG)
Figure 33. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue 2018-2023 ($ Millions)
Figure 34. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales 2018-2023 (KG)
Figure 35. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue 2018-2023 ($ Millions)
Figure 36. Americas Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country in 2022
Figure 37. Americas Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country in 2022
Figure 38. Americas Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2018-2023)
Figure 39. Americas Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2018-2023)
Figure 40. United States Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 41. Canada Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 42. Mexico Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 43. Brazil Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 44. APAC Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Region in 2022
Figure 45. APAC Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Regions in 2022
Figure 46. APAC Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2018-2023)
Figure 47. APAC Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2018-2023)
Figure 48. China Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 49. Japan Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 50. South Korea Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 51. Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 52. India Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 53. Australia Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 54. China Taiwan Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 55. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country in 2022
Figure 56. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country in 2022
Figure 57. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2018-2023)
Figure 58. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2018-2023)
Figure 59. Germany Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 60. France Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 61. UK Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 62. Italy Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 63. Russia Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 64. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country in 2022
Figure 65. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country in 2022
Figure 66. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2018-2023)
Figure 67. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2018-2023)
Figure 68. Egypt Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 69. South Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 70. Israel Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 71. Turkey Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 72. GCC Country Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 ($ Millions)
Figure 73. Manufacturing Cost Structure Analysis of Benign Prostatic Hyperplasia (BPH) Medication in 2022
Figure 74. Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Medication
Figure 75. Industry Chain Structure of Benign Prostatic Hyperplasia (BPH) Medication
Figure 76. Channels of Distribution
Figure 77. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Forecast by Region (2024-2029)
Figure 78. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share Forecast by Region (2024-2029)
Figure 79. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share Forecast by Type (2024-2029)
Figure 80. Global Benign Prostatic Hyperplasia (BPH) Medication
